Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Apparition: Thank you for providing FACTS that support my statements.

Even though you links don't work, let's supply the doses for each of these preclinical trials in RED

Notice that the dose used in these preclinical trials was much much higher tan even the current dose for the ninth cohort.

Kevetrin will need much much higher doses than the current dose in the ninth cohort to achieve similar results in humans.

http://cellceutix.com/kevetrin/#sthash.8iBdgCcB.mye9S5HA.dpbs

Good luck and GOD bless,

George

You said:

Kevetrin was studied in two cell lines of multi-drug resistant lung cancer. In two studies with the multi-drug resistant non-small cell lung carcinoma human cell line, A549, Kevetrin showed average tumor growth delay of 72% and average tumor volume reduction of 81% compared to controls. Both tumor growth delay and tumor volume reduction were also significantly greater with Kevetrin than with paclitaxel. (p<0.001). http://cellceutix.com/wp-content/upl...ancer-A549.pdf
Kevetrin is effective in mouse models of human lung cancer : A549 ? Kevetrin (200 mg/kg IP x 3 doses)
o 33% to 111% tumor growth delay compared to controls o 33% to 100% tumor growth delay compared to paclitaxel
(22 mg/kg IV x 4 doses)
? Only 3% to 4% decrease in animal weight

In two studies with the NCI-H1975 non-small cell lung carcinoma multi-drug resistant lung cancer, Kevetrin showed average tumor growth delay of 149% and tumor volume reduction of 94% compared to controls. Both tumor growth delay and tumor volume reduction were greater with Kevetrin than with paclitaxel (p<0.001). http://cellceutix.com/wp-content/upl...-NCI-H1975.pdf

Kevetrin is effective in mouse models of human lung cancer : NCI-H1975 ? Kevetrin (200 mg/kg IP x 3 doses)
o 142% to 156% tumor growth delay compared to controls
o 44% to 107% tumor growth delay compared to paclitaxel (22
mg/kg IV x 4 doses)
? No decrease in animal weight

In animal model testing on a taxane-resistant, estrogen receptor-negative breast cancer human cell line, MDA-MB-435s, tumor volume was reduced by 72% and tumor growth was delayed by more than 52% with Kevetrin when compared with paclitaxel. In a study with the MDA-MB-231 breast cancer cell line, Kevetrin demonstrated tumor growth delay of 90% compared to controls. http://cellceutix.com/wp-content/upl...DA-MB-435S.pdf

Kevetrin is effective in mouse models of human breast cancer: MDA-MB-435S ? Kevetrin (200 mg/kg IP x 3 doses)
o 62% to 68% tumor growth delay compared to controls o 62% to 79% tumor growth delay compared to paclitaxel
(22 mg/kg IV x 4 doses)
o 52% tumor growth delay compared to cisplatin (8mg/kg IP x 1 dose)

Colon Cancer Kevetrin showed tumor growth delay of 43% compared to controls and paclitaxel when tested on animals with HCT-15 P-glycoprotein drug resistant colon cancer. Kevetrin was studied in two experiments alone and in combination with 5-FU against the HT-29 cell line of colon cancer. Kevetrin alone demonstrated average tumor growth delay of 43% compared to controls. 5-FU alone showed an average tumor growth delay of 20%. The combination of Kevetrin and 5-FU resulted in an average tumor growth delay of 97%. http://cellceutix.com/wp-content/upl...oma-HCT-15.pdf

Kevetrin is effective in a mouse model of human colorectal adenocarcinoma: HCT-15 ? Kevetrin (200 mg/kg IP x 3 doses)
o 43% tumor growth delay compared to controls
o 43% tumor growth delay compared to paclitaxel (22 mg/kg IV x 4 doses)

Kevetrin was studied in multiple experiments alone and in conjunction with radiation against the SCC-15 cell line of head and neck cancer. Kevetrin alone showed an average tumor growth delay of 45% compared to controls, similar to radiation alone. When administered in conjunction with radiation, Kevetrin showed an average tumor growth delay of 116%. http://cellceutix.com/wp-content/upl...ation-with.pdf

Details: Nude mice bearing established tumors were treated with either 200 mg/kg Kevetrin intraperitoneally (IP) every other day for 3 doses or 3 Gy of local radiation daily for 5 doses or in combination given sequentially 1 week prior to or following Kevetrin treatment. Treatment with Kevetrin alone, radiation alone, or radiation followed by Kevetrin resulted in similar TGDs ranging from 10 to 14 days (32 to 45%). However, Kevetrin treatment followed 1 week later by radiation significantly increased TGD to 36 days (116%) relative to controls and to each treatment alone.